PMID- 26648744
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20151209
LR  - 20200929
IS  - 1178-6981 (Print)
IS  - 1178-6981 (Electronic)
IS  - 1178-6981 (Linking)
VI  - 7
DP  - 2015
TI  - Relative cost-effectiveness of using an extensively hydrolyzed casein formula 
      containing the probiotic Lactobacillus rhamnosus GG in managing infants with 
      cow's milk allergy in Spain.
PG  - 583-91
LID - 10.2147/CEOR.S89347 [doi]
AB  - OBJECTIVE: To estimate the cost-effectiveness of using an extensively hydrolyzed 
      casein formula containing the probiotic Lactobacillus rhamnosus GG (eHCF + LGG; 
      Nutramigen LGG) as a first-line management for cow's milk allergy compared with 
      eHCF alone, and amino acid formulae in Spain, from the perspective of the Spanish 
      National Health Service (SNS). METHODS: Decision modeling was used to estimate 
      the probability of immunoglobulin E (IgE)-mediated and non-IgE-mediated allergic 
      infants developing tolerance to cow's milk by 18 months. The models also 
      estimated the SNS cost (at 2012/2013 prices) of managing infants over 18 months 
      after starting a formula as well as the relative cost-effectiveness of each of 
      the formulae. RESULTS: The probability of developing tolerance to cow's milk by 
      18 months was higher among infants with either IgE-mediated or non-IgE-mediated 
      allergy who were fed eHCF + LGG compared with those fed one of the other 
      formulae. The total health care cost of initially feeding infants with eHCF + LGG 
      was less than that of feeding infants with one of the other formulae. Hence, eHCF 
      + LGG affords the greatest value for money to the SNS for managing both 
      IgE-mediated and non-IgE-mediated cow's milk allergy. CONCLUSION: Using eHCF + 
      LGG instead of eHCF alone or amino acid formulae for first-line management of 
      newly-diagnosed infants with cow's milk allergy affords a cost-effective use of 
      publicly funded resources because it improves outcome for less cost. A randomized 
      controlled study showing faster tolerance development in children receiving a 
      probiotic-containing formula is required before this conclusion can be confirmed.
FAU - Guest, Julian F
AU  - Guest JF
AD  - Catalyst Health Economics Consultants, Northwood, Middlesex, UK ; Faculty of Life 
      Sciences and Medicine, King's College, London, UK.
FAU - Weidlich, Diana
AU  - Weidlich D
AD  - Catalyst Health Economics Consultants, Northwood, Middlesex, UK.
FAU - Mascunan Diaz, J Ignacio
AU  - Mascunan Diaz JI
AD  - Centro de Salud de Paterna, Valencia, Spain.
FAU - Diaz, Juan J
AU  - Diaz JJ
AD  - Hospital Universitario Central de Asturias, Oviedo, Spain.
FAU - Ojeda, Pedro Manuel
AU  - Ojeda PM
AD  - Clinica de Asma y Alergia Doctores Ojeda, Valencia, Spain.
FAU - Ferrer-Gonzalez, J Pablo
AU  - Ferrer-Gonzalez JP
AD  - Hospital General de Requena, Valencia, Spain.
FAU - Gil, David
AU  - Gil D
AD  - Hospital Universitario Virgen de la Arrixaca, Murcia, Spain.
FAU - Onrubia, Isabel
AU  - Onrubia I
AD  - Centro de Salud Valle de la Oliva, Majadahonda, Spain.
FAU - Rincon Victor, Pedro
AU  - Rincon Victor P
AD  - Centro de Salud la Chopera, Alcobendas, Spain.
LA  - eng
PT  - Journal Article
DEP - 20151123
PL  - New Zealand
TA  - Clinicoecon Outcomes Res
JT  - ClinicoEconomics and outcomes research : CEOR
JID - 101560564
PMC - PMC4664436
OTO - NOTNLM
OT  - Lactobacillus rhamnosus GG
OT  - Spain
OT  - amino acid formula
OT  - cost-effectiveness
OT  - cow's milk allergy
OT  - extensively hydrolyzed formula
EDAT- 2015/12/10 06:00
MHDA- 2015/12/10 06:01
PMCR- 2015/11/23
CRDT- 2015/12/10 06:00
PHST- 2015/12/10 06:00 [entrez]
PHST- 2015/12/10 06:00 [pubmed]
PHST- 2015/12/10 06:01 [medline]
PHST- 2015/11/23 00:00 [pmc-release]
AID - ceor-7-583 [pii]
AID - 10.2147/CEOR.S89347 [doi]
PST - epublish
SO  - Clinicoecon Outcomes Res. 2015 Nov 23;7:583-91. doi: 10.2147/CEOR.S89347. 
      eCollection 2015.